(VIANEWS) – Shares of ERYTECH PHARMA (CAC 40: ERYP.PA) fell by a staggering 15.75% in 5 sessions from €0.91 to €0.77 at 01:56 EST on Monday, after four sequential sessions in a row of losses. CAC 40 is falling 1.78% to €7,187.27, following the last session’s downward trend.
ERYTECH PHARMA’s last close was €0.77, 65.86% under its 52-week high of €2.26.
About ERYTECH PHARMA
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ERYTECH PHARMA has a trailing twelve months EPS of €-0.93.
Volatility
ERYTECH PHARMA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.95%, a positive 2.10%, and a positive 5.68%.
ERYTECH PHARMA’s highest amplitude of average volatility was 3.30% (last week), 7.31% (last month), and 5.68% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
ERYTECH PHARMA’s EBITDA is 7.45.
Revenue Growth
Year-on-year quarterly revenue growth declined by 58.5%, now sitting on 2.2M for the twelve trailing months.
More news about ERYTECH PHARMA (ERYP.PA).
